News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cleveland Biolabs Inc. (CBLI) Announces Publication of Studies on Effect of Entolimod™ (CBLB502) on Graft-Versus-Tumor Activity in Models of Allogeneic Bone Marrow Transplantation



11/6/2012 9:49:34 AM

BUFFALO, N.Y., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) announced today the online publication in the Journal of Immunology of a study demonstrating efficacy of Entolimodâ„¢ (previously known as CBLB502) in improving the graft-versus-tumor (GVT) activity of allogeneic bone marrow transplantation (allo-BMT) in a mouse model. The reported studies were conducted by scientists at Roswell Park Cancer Institute (RPCI) and Cleveland BioLabs.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES